- Home
- HLVX
HLVX
HilleVax Inc.
as 12-17-2024 4:00pm EST
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 87.6M | IPO Year: | 2022 |
| Target Price: | $2.33 | AVG Volume (30 days): | 245.3K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.55 - $20.22 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest HilleVax Inc. News
HLVX Breaking Stock News: Dive into HLVX Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
3 US Penny Stocks With Market Caps Under $100M
GlobeNewswire
a month ago
HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Simply Wall St.
a month ago
Rave Restaurant Group And 2 Other Promising US Penny Stocks
Zacks
2 months ago
What Makes HilleVax (HLVX) a New Buy Stock
GlobeNewswire
4 months ago
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Pharmaceutical Technology
5 months ago
HilleVax slashes workforce by 40% after norovirus vaccine trial failure
GlobeNewswire
5 months ago
HilleVax Announces Reduction in Force
Zacks
5 months ago
After Plunging -86.93% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax (HLVX)
Compare HLVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HLVX HilleVax Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.